Home Emerging Therapy Update on Delivery of Emergency Epinephrine via Sublingual Film

Update on Delivery of Emergency Epinephrine via Sublingual Film


Back in January of 2018 we reported on the investigation of a novel way of administering epinephrine for anaphylaxis: a film placed under the tongue or on the side of the mouth where it quickly dissolves into the bloodstream.

The company – then called MonoSol Rx and now renamed Aquestive Therapeutics – has since gone public in an initial public offering that closed last July, raising $67.5 million. The company focuses on delivering medications via it’s PharmFilm® technology described above. A number of drugs delivered via PharmFilm have already received FDA approval.

Click to visit sponsor

According to their Full Year 2018 Financial Results press release published today, Aquestive held a meeting in January with Health Canada related to AQST-108, a formulation of epinephrine based on PharmFilm for the treatment of anaphylaxis. Based on the discussion, Aquestive is finalizing the clinical trial application for a study to evaluate a new formulation of the product that it plans to commence in the second quarter 2019.

Here is a video provided by Aquestive describing PharmFilm:

Print or share this article
Click to visit sponsor
Dave Bloom
Dave Bloom is CEO and "Blogger in Chief" of SnackSafely.com.

Find Allergy-Friendly Products